Actively Recruiting
Long-Term Open-Label Study of Treprostinil Palmitil Inhalation Powder for Pulmonary Hypertension with Interstitial Lung Disease
Led by Insmed Incorporated · Updated on 2026-10-27
344
Participants Needed
11
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research aims to evaluate the safety and tolerability of long-term use of Treprostinil Palmitil Inhalation Powder TPIP in participants with pulmonary hypertension associated with interstitial lung disease PH-ILD who have previously completed a related study. The purpose is to understand how well TPIP is tolerated over time and monitor any adverse effects while providing ongoing treatment. Participants who have finished the initial PH-ILD TPIP study will start with a 4-week double-dummy titration period using their stable dose combined with either TPIP or placebo. After this, they will receive open-label TPIP at a stable maintenance dose, with optional dose increases ranging from 80 to 1280 micrograms once daily, continuing for 104 weeks. Throughout the study, participants will be monitored regularly for treatment-emergent adverse events and changes in lung function, exercise capacity, biomarkers, and quality of life. Assessments include the 6-minute walk distance, forced vital capacity, forced expiratory volume, plasma concentrations of NT-proBNP, and questionnaires related to pulmonary fibrosis symptoms. Safety and effectiveness data will be collected up to 108 weeks, with ongoing monitoring of clinical worsening and major morbidity or mortality events.
CONDITIONS
Brief Title
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Research Team
I
Insmed Incorporated
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here